Claims for Patent: 9,421,223

Summary for Patent: 9,421,223

Title:	Nitric oxide generating medical devices
Abstract:	Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided.
Inventor(s):	Glauser; Thierry (Redwood City, CA), Pacetti; Stephen D. (San Jose, CA), Consigny; Paul M. (San Jose, CA)
Assignee:	Abbott Cardiovascular Systems Inc. (Santa Clara, CA)
Application Number:	14/622,131
Patent Claims:	1. A medical device comprising a metal complex comprising a metal and at least one ligand, at least one of the ligands being a bipyridine ligand; wherein the metal complex attaches to a surface of the medical device or a coating on the medical device, and wherein the metal complex catalyzes the in-vivo generation of nitric oxide. 2. The medical device of claim 1, wherein the in vivo generation of nitric oxide is nitric oxide generation in a blood stream or a tissue adjacent to the medical device. 3. The medical device of claim 1, wherein the coating on the medical device is present; and wherein the coating comprises a polymer to which the metal complex is attached. 4. The medical device of claim 1, wherein the medical device is a bioabsorbable stent comprising a polymer to which the metal complex is a attached. 5. The medical device of claim 1, wherein the metal of the metal complex comprises copper. 6. The medical device of claim 1, wherein the metal complex attaches to a surface of the medical device. 7. The medical device of claim 1, wherein the metal of the metal complex comprises a member of the group consisting of Cu, Co, Ni, Zn, Mn, Al, and Fe. 8. The medical device of claim 1, wherein the metal complex comprises an ion selected from the group consisting of Cu.sup.2+, Co.sup.2+, Ni.sup.2+, Zn.sup.2+, Mn.sup.2+, Al.sup.3+, and Fe.sup.3+. 9. The medical device of claim 1, further comprising a drug. 10. The medical device of claim 9, wherein the drug is selected from the group consisting of paclitaxel, docetaxel, estradiol, super oxide dismutases, tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, bioactive RGD, CD-34 antibody, abciximab (REOPRO), and combinations thereof. 11. The medical device of claim 9, wherein the coating on the medical device is present and the coating comprises the drug. 12. The medical device of claim 11, wherein the coating comprises a polymer to which the metal complex is attached. 13. The medical device of claim 11, wherein the drug is selected from the group consisting of paclitaxel, docetaxel, estradiol, super oxide dismutases, tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, bioactive RGD, CD-34 antibody, abciximab (REOPRO), and combinations thereof. 14. The medical device of claim 1, which is a stent. 15. The medical device of claim 1, which is a bioabsorbable stent. 16. The medical device of claim 1, wherein the nitric oxide is released from a nitrosylated biomolecule present in a blood stream or a tissue adjacent to the medical device. 17. The medical device of claim 1, wherein the nitric oxide is released from a nitrosylated protein or an S-nitrosothiol present in a blood stream or a tissue adjacent to the medical device. 18. A method of treating a disorder in a patient comprising implanting in the patient the medical device of claim 1, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof. 19. A method of treating a disorder in a patient comprising implanting in the patient the medical device of claim 10, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof. 20. A method of treating a disorder in a patient comprising implanting in the patient the medical device of claim 13, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof.

Details for Patent 9,421,223

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-03-29